Edwards Lifesciences shares surged 7.37% in after-hours trading on Thursday, following the release of second-quarter financial results that handily beat Wall Street estimates and a reaffirmed full-year profit outlook.

The company reported adjusted earnings per share of $0.78, exceeding the consensus estimate of $0.74. Quarterly sales came in at $1.741 billion, also ahead of the $1.700 billion analysts had expected. Both top and bottom lines showed double-digit growth compared to the same period last year.

Investor sentiment was further bolstered as the company reaffirmed its 2026 adjusted EPS guidance of $2.95 to $3.05, signaling confidence in its business trajectory despite macroeconomic uncertainties.